URMC / Research / Clinical Trials / Study Details

Study of Arimoclomol in Inclusion Body Myositis (IBM)

Basic Study Information

Purpose:
Funding Source - FDA OOPD. The purpose of this study is to evaluate the safety and efficacy of the study drug, Arimoclomol in IBM patients.

Location: University of Rochester

Lead Researcher (Principal Investigator)

Lead Researcher: Elizabeth Luebbe

Study Contact Information

Study Coordinator: Liz Luebbe
Phone: 585-275-7867
Email: elizabeth_luebbe@urmc.rochester.edu

Additional Study Details

Contact This Study

First Name *

This field is required

Middle Name

Last Name *

This field is required

Phone Number

I agree to be contacted by The University of Rochester Medical Center regarding participation in this study. *

You must agree to be contacted to continue.

Please call me during the day.

Please call me during the evening.

Message

Return to Search

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Wilmot Clinical Trials